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Exposure to inorganic arsenic (iAs) early in life is associated
with adverse health effects in infants, children, and adults, and
yet the biological mechanisms that underlie these effects are un-
derstudied. The objective of this research was to examine the pro-
teomic shifts associated with prenatal iAs exposure using cord
blood samples isolated from 50 newborns from Gómez Palacio,
Mexico. Levels of iAs in maternal drinking water (DW-iAs) and the
sum of iAs and iAs metabolites in maternal urine (U-tAs) were de-
termined. Cord blood samples representing varying iAs exposure
levels during the prenatal period (DW-iAs ranging from <1 to 236
g As/l) were analyzed for altered expression of proteins associ-
ated with U-tAs using a high throughput, antibody-based method.
A total of 111 proteins were identified that had a significant associ-
ation between protein level in newborn cord blood and maternal U-
tAs. Many of these proteins are regulated by tumor necrosis factor
and are enriched in functionality related to immune/inflammatory
response and cellular development/proliferation. Interindividual
differences in proteomic response were observed in which 30 new-
borns were “activators,” displaying a positive relationship between
protein expression and maternal U-tAs. For 20 “repressor” new-
borns, a negative relationship between protein expression level
and maternal U-tAs was observed. The activator/repressor sta-
tus was significantly associated with maternal U-tAs and head cir-
cumference in newborn males. These results may provide a criti-
cal groundwork for understanding the diverse health effects asso-
ciated with prenatal arsenic exposure and highlight interindividual
responses to arsenic that likely influence differential susceptibility
to adverse health outcomes.
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Over 100 million people worldwide, including pregnant
women and their unborn children, are exposed to levels of inor-
ganic arsenic (iAs) in their drinking water that exceed the World
Health Organization’s recommended limit 10 g As/l and are
considered detrimental to human health (Uddin and Huda, 2011;
WHO, 2006). Long-term exposure to iAs is associated with
the development of diverse chronic health conditions in adults
including cardiovascular disease, peripheral vascular disease,
neurological effects, diabetes mellitus, and cancers in several
organs including the lungs, liver, urinary bladder, prostate, and
skin (NRC, 2001; Rahman et al., 2009a). In addition to adverse
health effects in adults, exposure to high levels of iAs during
pregnancy is also associated with considerable risks to maternal
and fetal health including increased rates of spontaneous abor-
tion, preterm birth, stillbirth, decreased birth weight, and de-
creased size at birth (as reviewed in Vahter, 2009). In addition,
prenatal and/or early childhood exposure to iAs is associated
with delayed health effects, including increased rates of mor-
tality in young adults from both noncancerous diseases (e.g.,
bronchiectasis, acute myocardial infarction) and cancers of the
lung, urinary bladder, larynx, and liver (as reviewed in Farzan
et al., 2013). Together, these results suggest that the prenatal
period represents a particularly sensitive time to the toxic ef-
fects of iAs and the latent nature of several of these outcomes
suggests their impacts are likely underestimated (Vahter, 2009).
A limited number of studies have examined the effects of
prenatal iAs exposure in newborn cord blood at the molecu-
lar level. Previous studies have shown that newborns exposed
to iAs in utero have increased expression of proinflammatory
genes at both the transcriptional level and protein level in um-
bilical cord blood (Ahmed et al., 2011; Fry et al., 2007). There
is also substantial evidence that in utero iAs exposure can act as
an immunosuppressant, as prenatal exposure is associated with
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increased morbidity and mortality and reduced thymic index in
infants (Ahmed et al., 2012; Rahman et al., 2010; Raqib et al.,
2009). Taken together, these studies indicate that iAs can act
as an immunomodulatory agent in utero, a phenomenon which
may play a role in the development of the diverse adverse health
effects associated with iAs exposure.
We hypothesized that prenatal arsenic exposure is likely to
perturb the expression levels of proteins involved in a variety
of cellular processes in addition to immune function. In or-
der to better understand the molecular perturbations associated
with prenatal arsenic exposure, we conducted a proteomics as-
sessment of newborn cord blood from our recently established
prospective pregnancy cohort, herein termed the Biomarkers of
Exposure to ARsenic (BEAR) cohort. BEAR participants con-
sist of 200 mother-child pairs residing in Gómez Palacio, Du-
rango State, in the Lagunera region of northern Mexico. Im-
portantly, iAs-associated health effects such as diabetes melli-
tus (Del Razo et al., 2011) and skin lesions (Valenzuela et al.,
2009) have been reported in other northern and/or central Mex-
ican populations, and iAs concentrations in the drinking wa-
ter within Region Lagunera have been detected at levels that
exceed 600 g/l (Mendez-Gomez et al., 2008). In the present
study, we describe the proteomic shifts in newborn cord blood
associated with concentrations of maternal urinary arsenic and
identify significant changes in proteins involved in inflamma-
tion and immune function, cellular development and prolifera-
tion, and proteins with known relationships with iAs-associated
diseases. Tumor necrosis factor (TNF), which plays a critical
role in inflammation and cellular growth/development-related
signaling, was identified as an upstream regulator of many of
these proteins. Interestingly, interindividual differences in the
proteomic shifts were observed among the newborns and were
associated with birth outcome in a sex-dependent manner.
MATERIALS AND METHODS
Study subjects and sample collection. This study was ap-
proved by the Institutional Review Boards of the University
of North Carolina at Chapel Hill (no. 10-1583) and Universi-
dad Juárez del Estado de Durango (UJED). A total of 200 preg-
nant women residing in Gómez Palacio, in the State of Durango,
Mexico, were recruited at the General Hospital of Gómez Pala-
cio to participate in the BEAR prospective pregnancy cohort.
Requirements for participation in the study included (1) a 1 year
minimum residence in the Gómez Palacio region, (2) confirma-
tion of a singleton, intrauterine pregnancy without pregnancy
complications such as eclampsia or pre-eclamsia, and (3) good
overall health status (e.g., no signs of chronic or acute disease).
Each participant gave written, informed consent to participate
and agreed to provide urine samples, drinking water samples,
and to donate umbilical cord blood at delivery. Participants also
completed detailed questionnaires that gathered information on
various socioeconomic factors (e.g., age, education, occupation,
smoking status, and alcohol consumption) as well as potential
sources of iAs exposure (e.g., source of drinking water and vol-
ume consumed). Women could not be informed of their iAs ex-
posure during pregnancy as arsenic levels in drinking water and
urine were determined after delivery. However, they were in-
formed of their exposure status within 3 months after the births
of their children.
Within 4 weeks of newborn delivery, a representative drink-
ing water sample was collected by the research team at the
homes of each of the study participants. Maternal spot urine
samples were collected at the time of delivery, immediately
placed in a cryovial, and stored under liquid nitrogen. Birth
outcomes were assessed by the delivering physician. Fetal cord
blood was collected from newborns immediately after delivery
using a BD Vacutainer tube with clot activator (Becton, Dick-
inson and Company, Franklin Lakes, NJ). After clot formation,
each tube was centrifuged and the supernatant was collected and
stored at −70◦C until proteomic analyses were performed. All
samples were shipped on dry ice to the United States.
Determination of arsenic concentrations in drinking water
and maternal urine. The concentrations of iAs in drinking wa-
ter samples (g/l; DW-iAs) were measured at the Faculty of
Medicine, UJED, Gómez Palacio, Durango, Mexico using a
hydride generation-atomic absorption spectrometry (HG-AAS)
system (FIAS-100) as described previously (Le and Ma, 1998).
The limit of detection (LOD) for iAs in drinking water by HG-
AAS was 0.456 g/l.
All urine analyses were conducted at the Nutrition Obesity
Research Center, University of North Carolina at Chapel Hill,
Chapel Hill, NC. The specific gravity (SG) of each urine sam-
ple was determined using a handheld refractometer (Reichert
TX 400 no. 13740000; Reichert Inc., Depew, NY). Concentra-
tions of the sum of trivalent and pentavalent iAs (g As/l urine;
U-iAs) and the monomethylated and dimethylated metabolites
of iAs, namely, the sum of trivalent and pentavalent MMAs
(g As/l urine; U-MMAs) and the sum of trivalent and pen-
tavalent DMAs (g As/l urine; U-DMAs), respectively, were
determined by HG-AAS with cryotrapping (CT) as previously
described (Hernandez-Zavala et al., 2009). The LOD of urinary
iAs, MMAs, and DMAs by HG-AAS-CT were 0.2, 0.1, and 0.1
g As/l urine, respectively.
To account for differences in water composition between
urine samples, U-iAs, U-MMAs, and U-DMAs were ad-
justed by SG using the following equation: iAs × (mean SG-
1)/(individual SG-1) as previously described (Nermell et al.,
2008). Therefore U-iAs, U-MMAs, and U-DMAs were reported
as SG-adjusted values (g As/l urine). Total urinary arsenic (U-
tAs) was defined as the sum of SG-adjusted U-iAs, U-MMAs,
and U-DMAs in each urine sample (g As/l urine).
Assessment of protein expression in cord blood. The present
study for cord serum proteomic analyses examined 50 samples
obtained from mother-newborn pairs selected from the larger
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BEAR cohort (n = 200). The samples used in this study were
selected to include subjects exposed to varying levels of arsenic
as determined by both the sum of the levels of iAs and iAs
metabolites in maternal urine and iAs levels in drinking water.
The relative expression levels of 507 proteins across the 50 cord
serum samples were determined using the Biotin Label-based
Human Antibody Array I, L series 507 (RayBiotech, Norcross,
GA). Targets of the array include proteins involved in various
aspects of cellular signaling and include cytokines, chemokines,
growth factors, angiogenic factors, soluble receptors, and sol-
uble adhesion molecules. Protein labeling and hybridization
were carried out according to the manufacturer’s instructions
using 70 l of each cord serum sample. Briefly, this proce-
dure involved biotinylation of the primary amines of serum pro-
teins and hybridization of the labeled sample to a membrane
array containing antibodies specific for each of the 507 pro-
tein targets. Following incubation with a horseradish peroxidase
(HRP)-streptavidin conjugate, membrane-bound proteins were
revealed by chemiluminescence following incubation with a de-
tection buffer containing an appropriate HRP substrate. Two
types of positive controls are present on the array. The first is
a biotin-labeled protein that is independent of the sample that
is spotted on each array in a series of known concentrations
and therefore used to normalize signal intensities across arrays.
There is also an internal positive control which is an exogenous,
nonmammalian protein that is added to the serum sample prior
to biotinylation. This protein serves as a control for the biotin
labeling and sample incubation steps as well as serving as an
additional point of reference for normalization across multiple
arrays.
Statistical analyses. Statistical analyses were performed us-
ing SAS 9.3 (SAS Institute Inc., Cary, NC), Partek Genomics
Suite software (version 6.6; Partek, Inc., St Louis, MO), and
Spotfire software (TIBCO software, Somerville, MA). All data
were analyzed for their distribution patterns and homogeneity.
Maternal urine samples with concentrations of iAs, MMAs, or
DMAs below the LOD and DW samples with iAs below the
LOD were assigned a value equal to the LOD/
√
2. A regres-
sion model was used to quantify the relationship between SG-
adjusted maternal U-tAs as the independent variable and the
normalized, background-subtracted signal intensities of each of
the 507 protein array targets as the dependent variable. Poten-
tial confounders (e.g., maternal education, maternal age, ges-
tational age, newborn sex, and birth weight) were examined
for significant association with both the independent (U-tAs)
and dependent (protein expression) variables. Both Spearman’s
rank correlation and Pearson’s correlation were used to evaluate
associations between potential confounders and dependent and
independent variables. Significantly correlated variables were
further analyzed in multivariable adjusted regression models.
The models controlled for covariates identified based on corre-
lations (p < 0.1) with the exposure (U-tAs) and outcome (pro-
tein levels). Based on these criteria, both newborn sex and birth
weight were included in the final regression model. The regres-
sion model was used to identify all proteins that had a statisti-
cally significant relationship between expression level and U-
tAs (p < 0.05) where false discovery (type II error) was con-
trolled using a q-value <0.1.
A supervised analysis was performed to identify the activator
and repressor proteomic groupings. First, newborns were clas-
sified into a low exposure class (LEC) or a high exposure class
(HEC) based on median maternal U-tAs (30.7 g/l). Average
protein expression levels were determined within these classes
and the expression level of each protein was compared to the av-
erage protein expression in the exposure categories. Activators
were classified as newborns where the majority of assayed pro-
tein demonstrated quantitatively higher expression levels rela-
tive to the average protein expression for the HEC. Repressors
were classified as newborns where the majority of assayed pro-
teins demonstrated quantitatively lower expression levels rel-
ative to the average protein expression for the HEC. The rela-
tionship between newborn activator/repressor status and mater-
nal characteristics, arsenic exposure indicators, and birth out-
comes were determined using a Wilcoxon Rank Sum test and
Chi-Square tests.
Functional analyses of proteins. Fetal cord blood pro-
teins with statistically significant associations between pro-
tein level and U-tAs were analyzed for associated biolog-
ical functions, canonical pathways, predicted upstream reg-
ulatory molecules, and interacting molecular networks us-
ing Ingenuity Pathway Analysis software (Ingenuity Systems,
Redwood City, CA). The proteins were also analyzed for
associated canonical pathways using the Kyoto Encyclope-
dia of Genes and Genomes (KEGG; www.genome.jp/kegg).
Benjamini-Hochberg-corrected p-values were reported for all
canonical pathways.
RESULTS
Characteristics of Study Population
Maternal demographic characteristics, indicators of iAs ex-
posure, and pregnancy and birth outcomes of the mother-child
pairs selected for analysis here (n = 50) are described in Sup-
plementary table 1. Indicators of iAs exposure included the con-
centration of iAs in maternal drinking water (g As/l; DW-iAs)
and urinary concentrations of iAs and its monomethylated and
dimethylated metabolites, MMAs and DMAs, respectively, in
maternal urine (g As/l; U-iAs, U-MMAs, and U-DMAs, re-
spectively). For comparative purposes, these data are also pro-
vided for the overall BEAR cohort (n = 200; Supplementary
table 1).
The levels of iAs in drinking water samples of the cohort (n
= 50) ranged from below the LOD of 0.456 up to 236 g As/l.
Of these drinking water samples, 30 (60%) had DW-iAs that
exceeded the WHO standard of 10 g As/l and 25 (50%) ex-
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ceeded Mexico’s standard of 25 g As/l. The mean and median
DW-iAs of the cohort were 53.9 and 24.2 g As/l, respectively.
As observed with DW-iAs, there was a range of U-iAs, U-
MMAs, and U-DMAs (n = 50; Supplementary table 1). Most of
the urine samples demonstrated detectable levels of U-iAs and
U-MMAs with ranges of <LOD–23.0 g As/l and <LOD–18.2
g As/l, respectively. DMAs was detected in all urine samples
and ranged from 5.3 to 292.5 g As/l. Total maternal urinary
arsenic (U-tAs), defined as the sum of U-iAs, U-MMAs, and
U-DMAs, ranged from 6.18 to 319.74 g As/l. The average
proportions of U-tAs comprising iAs, MMAs, and DMAs were
6.5% iAs, 6.5% MMAs, and 87.0% DMAs, respectively. There
was a significant positive correlation between DW-iAs and U-
tAs in the cohort (n = 50; r = 0.88; p < 0.001).
Analysis of the cohort for various birth outcomes showed that
all pregnancies resulted in a live, singleton birth of which 54%
were males. More detailed birth information is found in Supple-
mentary table 1.
Identification of Cord Blood Proteins Associated with
Maternal U-tAs
Multivariable regression analyses identified 111 proteins for
which there was a statistically significant association between
protein abundance in newborn cord blood and maternal U-
tAs (Supplementary table 2). These analyses demonstrated that
although these proteins were associated with maternal U-tAs
across all subjects (p < 0.05, q < 0.1), there were two distinct
groups of newborns that could be identified based on differ-
ences in proteomic response. Specifically, a supervised analysis
was used to compare each newborn’s individual proteomic re-
sponse to the average proteomic response, analyzed in the con-
text of prenatal arsenic exposure (i.e., U-tAs). These analyses
resulted in the identification of two classes of newborns, those
who demonstrated general increased expression levels of the
111 proteins as maternal U-tAs increased (n = 30) and were
subsequently termed “activators” (Fig. 1A, Supplementary ta-
ble 2). Similarly, there were newborns who in general showed
decreased expression of the 111 proteins as maternal U-tAs in-
creased (n = 20) and were subsequently referred to as “repres-
sors” (Fig. 1B, Supplementary table 2).
Associations Between Activator/Repressor Status with
Maternal Characteristics, Arsenic Exposure, and Birth
Outcomes
The activator/repressor status was analyzed for association
with various maternal characteristics, indicators of iAs exposure
and metabolism, and selected birth outcomes. There was no dif-
ference in maternal characteristics, namely age at delivery, ed-
ucation level, smoking status, or alcohol consumption between
activators and repressors (Supplementary table 3).
Overall, DW-iAs was similar between the activator and re-
pressor groups (p = 0.35) with activators ranging in exposure
levels from <LOD (<0.456 g As/l) up to 212.1 g As/l and
repressors ranging in exposure levels from <LOD up to 235.6
g As/l (Supplementary table 3). When the sex of the newborns
was considered separately for analyses, there was no signifi-
cant relationship between DW-iAs and activator/repressor sta-
tus (p = 0.42 for males; p = 0.60 for females). Likewise, U-tAs
was not significantly different between the activator/repressor
groups (Supplementary table 3).
When newborn males and females were analyzed separately,
there was a significant difference in U-tAs between the activa-
tors and repressors in newborn males (p = 0.02) but not in new-
born females (p = 0.90) (Supplementary table 3). As observed
with U-tAs, there was a statistically significant difference in U-
DMAs and activator/repressor status in newborn males (p =
0.03) but not in newborn females (p = 0.82). A comparison be-
tween activator males versus activator females revealed there
was no significant difference in U-tAs (p = 0.07) or U-DMAs
(p = 0.56) between them. There were no statistically signifi-
cant differences between indicators of iAs exposure or indica-
tors of iAs metabolism (e.g., %MMAs, DMAs/MMAs) with
activator/repressor status observed across all newborns, new-
born males only, or newborn females only (Supplementary table
3).
Of the measured birth outcomes, a significant difference in
head circumference was observed between activator and repres-
sor newborn males (p = 0.01), in which activator males had a
smaller head circumference (mean = 34.5 cm; median = 35 cm;
range 32–37 cm) than repressor males (mean = 36.1 cm; median
36 cm; range 35–37 cm). There was no significant difference ob-
served between activator and repressor newborn females (p =
0.90). There were no other statistically significant differences
between activator/repressor status and any of the other mea-
sured birth outcomes including method of delivery, sex of new-
born, gestational age, newborn weight, five minute Appearance,
Pulse, Grimace, Activity, Respiration (APGAR) score, placen-
tal weight, newborn crown to heel length, and newborns clas-
sified as small for gestational age (SGA), large for gestational
age (LGA), or born at low birth weight (LBW) (Supplementary
table 3).
Pathway and Network Analysis Reveals Enrichment of Proteins
Involved in Development, Proliferation, and Inflammation
To gain insight into the biological role of the 111 proteins,
functional analyses were performed. Analysis of the most sig-
nificant enriched canonical pathways revealed they could be
summarized into two major functional categories, namely those
involved in (1) cellular growth/proliferation and/or develop-
ment and those involved in (2) immune response/inflammation.
Specifically, the pathways associated with growth/proliferation
and/or development included the transforming growth factor
beta (TGF-) signaling pathway (p = 5.7 × 10−13) and the
mitogen-activated protein kinase (MAPK) signaling pathway
(p = 5.6 × 10−2), among others (Supplementary table 4A and
B). Additionally, inflammation-associated pathways were iden-
tified including the nuclear factor kappa-light-chain-enhancer
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FIG. 1. Relative expression levels of U-tAs-associated cord blood proteins differ between newborns. Heat maps illustrate the relative protein expression
levels of 111 U-tAs-associated cord blood proteins in activator newborns (A) and repressor newborns (B). Expression values for each protein are mean centered
with high relative expression indicated in red and low relative expression indicated in blue. U-tAs: sum of inorganic arsenic (iAs) and its monomethylated and
dimethylated metabolites (MMAs and DMAs, respectively) in maternal urine (g As/l urine).
of activated B cells (NF-B) signaling pathway (p = 1.36 ×
10−5) (Supplementary table 4A and B).
In support of these results, network analyses revealed five sig-
nificant protein clusters with functions associated with develop-
ment and immune response (Supplementary table 4C). The two
most significant networks had central hubs consisting of stress-
responsive molecules, namely the transcription factor NF-B
and extracellular signal-regulated kinases 1/2 (ERK1/2) (Sup-
plementary fig. 1A and B respectively; Supplementary table
4C). The most significant molecular network containing NF-B
as a central hub comprises several proteins involved in immune
response (Supplementary fig. 1A).
The molecular network centered around ERK1/2
MAPK also contains several proteins involved in immune
response/inflammation (Supplementary fig. 1B) as well as
several proteins associated with development including bone
morphogenic protein 2 (BMP2), bone morphogenic protein
receptor 2 (BMPR2), neuregulins 1 and 3 (NRG1 and NRG3,
respectively), and transforming growth factor beta receptor 2
(TGFBR2).
The 111 proteins were also analyzed for associated diseases
and disorders, in which diseases related to the immune sys-
tem and inflammation were among the most significant (Table
1). The pathway-level analyses identified several inflammation-
associated diseases associated with arsenic exposure, including
cancers, atherosclerosis, and liver fibrosis (Supplementary table
4A and B).
TNF Predicted to Regulate the Fetal Proteome
Analysis was performed on the 111 proteins to identify key
upstream molecules including signaling molecules and/or tran-
scription factors that are predicted to regulate their expression.
This analysis uncovered a significant regulatory network (p
= 6.14 × 10−25) predicted to mediate 62 (∼56%) of the U-
tAs-associated proteins. This network contains known interac-
tions among 16 proteins or protein complexes consisting pri-
marily of cytokines and transcription factors that play a role
in inflammation/immune response, the majority of which (12;
75%) are predicted to be activated based on the expression pro-
files of the U-tAs proteins in the activator group (Fig. 2). This
analysis highlights the potential role of TNF as a key regulator in
the U-tAs-associated proteomic response in newborn cord blood
and indeed of the 111 U-tAs-associated proteins, 45 (∼40%)
are known regulatory targets of TNF (Fig. 3). These proteins
include those involved in immune response such as chemokine
(C-X-C motif) ligand 16 (CXCL16), chemokine (C-X-C motif)
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TABLE 1
Most Significant Diseases and Disorders of the 111 U-tAs-Associated Cord Blood Proteins
Disease/disorder Average p-value Number of proteins
Inflammatory response 1.21 × 10−05 57
Cardiovascular disease 7.93 × 10−06 35
Connective tissue disorders 1.93 × 10−05 31
Immunological disease 1.50 × 10−05 42
Inflammatory disease 1.00 × 10−05 44
FIG. 2. Regulatory network of U-tAs-associated cord blood proteins. An upstream network predicted to regulate the expression of the majority (∼56%) of the
111 U-tAs-associated cord blood proteins was identified. Proteins are displayed as predicted to be activated (orange) or inhibited (blue) with increasing maternal
U-tAs, a trend representative of the activator newborn response. HIF1A: hypoxia inducible factor 1, alpha subunit; IFNG: interferon gamma; IKBKB: inhibitor
of kappa light polypeptide gene enhancer in B-cells, kinase beta; IL1B: interleukin 1 beta; IRF3: interferon regulatory factor 3; IRF8: interferon regulatory factor
8; NFKB complex: nuclear factor kappa light chain enhancer of activated B cells complex; NFKB1: nuclear factor of kappa light polypeptide gene enhancer in
B-cells 1; NFKBIA: nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; NFKBIB: nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor, beta; REL: v-rel reticuloendotheliosis viral oncogene homolog (avian); RELA: v-rel reticuloendotheliosis viral oncogene homolog
A (avian); SMAD3: SMAD family member 3; STAT1: signal transducer and activator of transcription 1; TGFB1: transforming growth factor beta 1; TNF: tumor
necrosis factor.
ligand 1 (CXCL1), and macrophage migration inhibitory fac-
tor (MIF) as well as proteins involved in development such as
epiregulin (EREG) and TGFBR2.
Comparison with Reported Cord Blood Gene/Protein Changes
in Other Human Cohorts
The 111 proteins identified here were compared with known
prenatal arsenic-responsive genes (Fry et al., 2007) and pre-
natal arsenic-responsive proteins (Ahmed et al., 2011). Fry
et al. (2007) identified 447 transcripts that were differentially
expressed in cord blood leukocytes from newborns born to
arsenic-exposed versus arsenic-unexposed mothers in Thailand
(Fry et al., 2007). Of these 447 transcripts, 30 represented
genes in common with the 507 proteins probed on the array
in the present study, and six (5%) were among the 111 U-tAs-
associated proteins. The proteins encoded by these six genes
were: chemokine (C-C motif) receptor 2 (CCR2), chemokine
(C-C motif) receptor 3 (CCR3), CXCL1, chemokine CXCL16,
CXCR4, and EREG. In the present study, each of these proteins
displayed increased expression levels in activator newborns as
U-tAs increased.
Ahmed et al. (2011) analyzed 18 cord blood proteins for as-
sociations with maternal U-tAs in Bangladeshi newborns. Of
these 18 proteins, 15 were represented on the arrays in the cur-
rent study, however, none of these proteins were among the 111
U-tAs-associated proteins identified here. Ahmed et al. (2011)
identified four cord blood proteins, namely interleukin 1 beta
(IL1B), interleukin 8 (IL8), interferon gamma (IFNG), and TNF
that had expression levels that formed U-shaped curves across
quartiles of maternal U-tAs. TNF, INFG and IL1B are compo-
nents of the upstream regulatory network of U-tAs-associated
cord blood proteins described in the current study (Fig. 2).
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FIG. 3. TNF-associated cord blood proteins. TNF is predicted to regulated the expression of the majority (n = 45) of the U-tAs-associated proteins. Proteins
are displayed as predicted to be activated (orange), up-regulated (red), or down-regulated (green) with increasing maternal U-tAs, a trend representative of the
activator newborn response. TNF: tumor necrosis factor. Complete names of the U-tAs-associated proteins are provided in Supplementary table 1.
DISCUSSION
Prenatal iAs exposure is clearly linked to adverse health ef-
fects such as poor birth outcomes, increased susceptibility to
opportunistic infections in infancy and childhood, and altered
disease risk later in life (Farzan et al., 2013; Vahter, 2009). In
the present study, we set out to identify biological pathways that
may be altered at the protein level by in utero iAs exposure us-
ing a proteomics assessment of more than 500 proteins in new-
born cord blood. The results presented here represent the most
comprehensive proteomic analysis of the effects of in utero iAs
exposure in human populations to date and may help identify
proteins that may be used as biomarkers of exposure and/or pre-
dictors of disease risk.
Using samples from 50 mother-child pairs from the recently-
established BEAR prospective pregnancy cohort, a total of 111
cord blood proteins were identified with expression levels as-
sociated with maternal U-tAs. When analyzed in the context of
their proteomic responses, the newborns could be divided into
two distinct groups based on the relationship between the ex-
pression levels of these 111 proteins and maternal U-tAs. Most
newborns (n = 30; 60%) were activators, who in general demon-
strated a positive association between U-tAs and protein expres-
sion, whereas the remainder (n = 20; 40%) were repressors,
in which cord blood protein expression levels and U-tAs had
an inverse relationship. It is important to note that the identi-
fication of the activator and repressor newborns, with poten-
tially high biological relevance, required an analysis of each
newborn’s proteomic response relative to the average newborn
proteomic response. A relationship was identified between this
activator/repressor status, maternal indicators of arsenic ex-
posure (i.e., U-tAs and U-DMAs), and head circumference in
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newborn males. Unexpectedly, we observed this relationship at
lower doses of U-tAs within the cohort, as activator males were
associated with reduced average U-tAs, U-DMAs, and head cir-
cumference relative to repressor males. Few studies have exam-
ined the effects of prenatal arsenic exposure on newborn head
circumference, but two separate studies reported negative asso-
ciations between newborn head circumference and arsenic lev-
els in cord blood (Guan et al., 2012) and between U-tAs and
newborn head circumference, chest circumference, and size at
birth at low levels of maternal arsenic exposure (U-tAs < 100
g/l) (Rahman et al., 2009b). These relationships between pre-
natal arsenic exposure and head circumference may be signifi-
cant for health effects later in life as in general, there is a positive
relationship between head circumference at birth and childhood
cognitive ability (Heinonen et al., 2008; Veena et al., 2010).
Furthermore, inverse associations between iAs exposure and
cognitive function have been reported in children (Rosado et al.,
2007; von Ehrenstein et al., 2007; Wasserman et al., 2007) but
little is known in terms of the impact of prenatal exposure on
intellectual function and must be addressed in future studies.
It is important to highlight that the relationship between U-
tAs and newborn head circumference in activator newborn boys
was not only dependent on activator/repressor status but was
also sex-dependent. Various other sex-specific effects of iAs ex-
posure have been reported in the literature. For instance, obser-
vations in exposed populations suggest women are more likely
to develop several internal cancers whereas men are more likely
to develop skin lesions, and different carcinogenic effects are
observed between adult male and female mice transplacentally
exposed to iAs in utero (as reviewed in Vahter et al., 2007). Of
potential interest to the current study, research based in Torreón,
Mexico demonstrated that boys and girls differed in terms of
cognitive deficiencies associated with iAs exposure (Rosado
et al., 2007). More cognitive deficiencies were observed in boys
than girls and in some cases, cognitive deficits were only noted
at low levels of exposure (U-tAs < 50 g/l). The identification
of specific cognitive effects at low levels of exposure is espe-
cially interesting considering the association between lower ma-
ternal U-tAs and reduced head circumference in activator boys
in the present study. Altogether, these data suggest the relation-
ship between activator status, maternal U-tAs and sex-specific
trends in birth outcomes warrant further study in terms of later-
life health effects.
Many of the identified U-tAs-associated proteins have known
links to development, inflammation/immune response, inflam-
matory diseases, and chronic diseases associated with arsenic
exposure. In addition, this analysis revealed that many of
the U-tAs-associated proteins are regulated by TNF, which is
known to be involved in diverse processes in the cell includ-
ing apoptosis, necrosis, inflammation, cell survival, angiogen-
esis, and cell migration (Wajant, 2009). Of potential interest
to the birth outcomes cited above, proteins with known links
to neurological, brain, and/or skull development were among
the TNF-associated and/or ERK1/2-associated proteins such as
TGFBR2, BMP2, BMPR2, and NRG1 (Britsch, 2007; Monuki
et al., 2001; Seo and Serra, 2009). Therefore, these proteins may
serve as novel targets for understanding arsenic-associated im-
pacts on fetal growth and neurological development and disease.
The identification of inflammation/immune response as a
major function associated with the U-tAs-associated proteins
and their predicted upstream regulatory proteins/complexes is
of particular interest. In relationship with maternal U-tAs, these
proteins were largely predicted to be activated or up-regulated
in the majority of newborns (i.e., activator newborns), which
support the proinflammatory responses observed at the tran-
scriptional level (Fry et al., 2007) and protein level (Ahmed
et al., 2011) in the cord blood of arsenic-exposed newborns
in other populations. Taken together, these data suggest that
proinflammatory signaling is a conserved response to prenatal
arsenic exposure in newborns across populations. Importantly,
long-term proinflammatory signaling is implicated as a critical
mechanism by which arsenic induces carcinogenic effects (as
reviewed in Valko et al., 2006). In the current study, several U-
tAs-associated pathways, proteins and upstream regulators of
these proteins have known links to inflammatory diseases as-
sociated with arsenic exposure. These included pathways asso-
ciated with various cancers, hepatic fibrosis, and atherosclero-
sis. TNF, identified here as a putative master regulator of the
proteomic response to prenatal arsenic exposure, plays a key
role in the regulation of immune/inflammatory responses and
is strongly implicated in chronic inflammatory disease develop-
ment (Holtmann and Neurath, 2004). Polymorphisms within the
TNF promoter are associated with increased levels of TNF and
a higher incidence of skin lesions, respiratory diseases, and con-
junctivitis in iAs-exposed individuals in West Bengal (Banerjee
et al., 2011). TNF is also implicated as a player in inflamma-
tory reactions in the liver leading to tissue injury and fibrosis in
arsenic-exposed mice (Das et al., 2005). The proinflammatory,
proangiogenic growth factor CXCL1 is a potential biomarker
of prenatal arsenic exposure (Fry et al., 2007) that has been
associated with an invasive phenotype and higher pathological
stage in bladder cancers (Kawanishi et al., 2008) and is asso-
ciated with hepatocellular carcinoma (Wu et al., 2009). MIF
is a regulator of immune/inflammatory responses and is impli-
cated in angiogenesis in all stages of cancer development (Babu
et al., 2012). It is important to note that although the expres-
sion of these inflammation-associated proteins is generally up-
regulated in relationship to U-tAs in activator newborns, these
proteins are generally down-regulated in relationship to U-tAs
in repressor newborns. Although a persistent inflammatory state
can be detrimental to human health, impaired immune function,
which has also been associated with prenatal arsenic exposure
in human populations (Ahmed et al., 2012; Rahman et al., 2010;
Raqib et al., 2009), can also play a role in the development of
acute disease as well as increase the susceptibility to the de-
velopment of chronic diseases later in life. Because markers of
immunosuppression and inflammation have been observed si-
multaneously in arsenic-exposed populations (Soto-Pena et al.,
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2006), it is likely that these two seemingly divergent effects both
play a role in the development of the diverse adverse health ef-
fects associated with iAs exposure. In support of this, the results
of the current study suggest there may be a relationship between
activator/repressor newborn status, differential modulation of
proteins involved in host defense, and variation in disease sus-
ceptibility.
Although the current study identified 111 cord blood proteins
that were associated with maternal U-tAs and thus vastly in-
creased the knowledge of the proteomic response to arsenic ex-
posure in utero, it is not without limitations. The sample size
in the present pilot study was limited based on proteomic as-
say cost. Thus, the dose-responsive and sex-dependent trends
reported here should clearly be replicated in larger cohorts. In
addition, the relationship between maternal U-tAs, cord blood
levels of arsenic (BA), and health outcomes will be examined,
as there are indications that the relationship between U-tAs and
BA may be sex-dependent (Hall et al., 2006). Moreover, it is
not possible in the present study to determine correlative ver-
sus causal relationships between U-tAs, proteomic responses,
and birth outcomes, which will require controlled toxicological
studies in animal models.
The relevance of alterations in the expression of the identified
proteins in exposed newborns to the susceptibility of chronic
diseases that develop later in life is currently unknown. These
altered profiles may be linked to epigenetic reprogramming that
occurs in the fetal environment in association with iAs expo-
sure. Through the altered, persistent expression of key genes,
epigenetic reprogramming has been implicated as a plausible
link between prenatal exposure to environmental toxicants such
as iAs and altered disease risk in adulthood (Bollati and Bac-
carelli, 2010; Jirtle and Skinner, 2007). Therefore, the stability
of these altered proteomic profiles and their relationship with al-
terations to the epigenome and disease susceptibility must be in-
vestigated in future studies. The results observed here will serve
as an important foundation in efforts to elucidate the complex
relationship between prenatal arsenic exposure, interindividual
proteomic responsiveness, and differences in disease suscepti-
bility.
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